Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (11)

2024

  1. Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not

    European Urology

  2. Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

    Translational Andrology and Urology

  3. Endourological panorama and current state of training in endourology among European teaching hospitals

    Minerva Urology and Nephrology

2023

  1. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis

    Clinical Oncology, Vol. 35, Núm. 12, pp. e676-e688

  2. Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up

    European Urology Focus, Vol. 9, Núm. 2, pp. 325-332

  3. Oncological and Renal Function Outcomes in Patients Who Underwent Simultaneous Radical Cystectomy and Nephroureterectomy for Synchronous or Metachronous Panurothelial Carcinoma

    Urology, Vol. 172, pp. 157-164

2022

  1. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 11, pp. 491.e11-491.e19

  2. Corrigendum to <‘Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center’> <[Volume 40, Issue 7, July 2022, Pages 345.e19-345.e23]> (Urologic Oncology: Seminars and Original Investigations (2022) 40(7) (345.e19–345.e23), (S1078143922000679), (10.1016/j.urolonc.2022.02.018))

    Urologic Oncology: Seminars and Original Investigations

  3. Evidence-based Medicine: Perceptions, Attitudes, and Skills Among European Urology Residents

    European Urology Open Science, Vol. 45, pp. 44-49

  4. Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center

    Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 7, pp. 345.e19-345.e23

2021

  1. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 1, pp. 76.e9-76.e14